Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Top Page
Pacira Pharmaceuticals
(NASDAQ:PCRX)
61Neutral
Positive Factors
Legal Settlement
The likelihood of an Exparel settlement with eVenus/Jiangsu Hengrui is considered high, which contributes to a positive outlook for the stock.
Strategic Plan
The strategic plan aims for double-digit CAGR growth in product revenues and a 5% improvement in gross margins.
Negative Factors
Product Value Proposition
Mixed KOL commentary from a Weill Cornell anesthesiologist raises questions about Exparel's value proposition.
Pacira Pharmaceuticals (PCRX) vs. S&P 500 (SPY)
Market Cap
$1.07B
Dividend YieldN/A
Average Volume (3M)840.97K
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue Growth3.85%
EPS Growth-339.15%
CountryUS
Employees712
SectorHealthcare
Sector Strength78
IndustryPharmaceuticals
Share Statistics
EPS (TTM)-2.20
Shares Outstanding46,276,240
10 Day Avg. Volume1,017,357
30 Day Avg. Volume840,972
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3557.49
Price to Cash Flow (P/CF)8.20
P/FCF Ratio8.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$32.83Price Target Upside41.75% Upside
Rating ConsensusHold
Number of Analyst Covering8
Pacira Pharmaceuticals Business Overview & Revenue Model
Company DescriptionPacira Pharmaceuticals, Inc. (PCRX) is a pharmaceutical company that focuses on developing and commercializing non-opioid pain management and regenerative health solutions. The company is known for its flagship product, EXPAREL, a long-acting local anesthetic used for post-surgical pain control. Pacira also offers other innovative pain management therapies that aim to reduce the reliance on opioids, thereby addressing a significant public health concern.
How the Company Makes MoneyPacira Pharmaceuticals generates revenue primarily through the sale of its products, with EXPAREL being the key driver of its income. The company earns money by selling EXPAREL directly to hospitals, ambulatory surgical centers, and other healthcare facilities. Additionally, Pacira has strategic partnerships and collaborations with other healthcare organizations to expand its market reach and product offerings, which also contribute to its revenue streams. The company's efforts to promote the benefits of non-opioid pain management solutions are critical to its financial success, as they help increase the adoption and utilization of its products.
Pacira Pharmaceuticals Financial Statement Overview
Summary
Pacira Pharmaceuticals shows steady revenue growth and strong cash flow, but faces significant profitability challenges and moderate debt management concerns. Operational efficiency improvements are needed.Income Statement
Pacira Pharmaceuticals has shown a mixed performance in its income statement. Revenue growth has been positive over the years, with a 3.85% increase from 2023 to 2024 and a 1.22% increase from 2022 to 2023. However, profitability metrics have declined sharply, with a negative EBIT and EBITDA margin in 2024, indicating operational challenges. The net profit margin turned negative in 2024, reflecting a significant dip from the previous positive results.55
Neutral
Balance Sheet
The company's balance sheet reveals moderate stability. The debt-to-equity ratio improved from 2023 to 2024, indicating better leverage management. However, the equity ratio remained fairly stable at around 50%. Return on equity took a hit in 2024, turning negative, which is a concern for profitability and shareholder returns.60
Neutral
Cash Flow
Cash flow metrics are relatively strong, with a notable free cash flow growth rate of 28.15% from 2023 to 2024. Operating cash flow to net income ratio improved significantly, suggesting better cash management despite the negative net income. Free cash flow remains robust, providing a buffer against operational downturns.70
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 700.97M | 674.98M | 666.82M | 541.53M | 420.83M | Gross Profit |
| 700.97M | 490.31M | 467.53M | 401.28M | 303.50M | EBIT |
| -73.37M | 87.67M | 60.02M | 131.06M | 46.35M | EBITDA |
| 29.12M | 157.58M | 144.78M | 118.47M | 71.42M | Net Income Common Stockholders |
| -99.56M | 41.95M | 15.91M | 41.98M | 145.52M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 276.77M | 278.58M | 288.65M | 656.41M | 521.66M | Total Assets |
| 1.55B | 1.57B | 1.68B | 2.08B | 1.27B | Total Debt |
| 490.00M | 586.04M | 763.39M | 1.13B | 541.13M | Net Debt |
| 213.22M | 432.75M | 659.25M | 543.27M | 441.17M | Total Liabilities |
| 775.17M | 704.26M | 906.19M | 1.34B | 654.83M | Stockholders Equity |
| 778.35M | 870.13M | 775.01M | 730.41M | 619.69M |
| Cash Flow | Free Cash Flow | |||
| 178.75M | 139.49M | 115.20M | 79.85M | 39.23M | Operating Cash Flow |
| 189.39M | 154.65M | 145.27M | 125.72M | 77.03M | Investing Cash Flow |
| -83.28M | 77.54M | -225.19M | -20.79M | -277.61M | Financing Cash Flow |
| 17.36M | -183.03M | -401.53M | 380.69M | 222.30M |
Pacira Pharmaceuticals Technical Analysis
Neutral
23.16
Price Trends
23.56
Negative
20.66
Positive
20.38
Positive
Market Momentum
-0.31
Positive
40.82
Neutral
14.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCRX, the sentiment is Neutral. The current price of 23.16 is below the 20-day moving average (MA) of 24.92, below the 50-day MA of 23.56, and above the 200-day MA of 20.38, indicating a neutral trend. The MACD of -0.31 indicates Positive momentum. The RSI at 40.82 is Neutral, neither overbought nor oversold. The STOCH value of 14.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PCRX.
Pacira Pharmaceuticals Risk Analysis
Pacira Pharmaceuticals disclosed 68 risk factors in its most recent earnings report. Pacira Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pacira Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $1.83B | 24.91 | 7.55% | ― | 8.94% | 5171.26% | |
61 Neutral | $1.07B | ― | -12.08% | ― | 3.85% | -339.15% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
47 Neutral | $356.45M | ― | -39.08% | 5.92% | -4.98% | -910.57% | |
32 Underperform | $82.70M | ― | -51.32% | ― | ― | 58.00% |
* Healthcare Sector Average
Performance Comparison
PCRX
Pacira Pharmaceuticals
23.16
-7.40
-24.21%
RDUS
Schnitzer Steel Industries
13.52
-4.91
-26.64%
SUPN
Supernus Pharmaceuticals
32.02
-0.90
-2.73%
CRBP
Corbus Pharmaceuticals
6.88
-37.70
-84.57%
Pacira Pharmaceuticals Earnings Call Summary
Earnings Call Date: Feb 27, 2025 | % Change Since: -8.75% | Next Earnings Date: Apr 30, 2025
Earnings Call Sentiment Positive
Pacira BioSciences reported strong financial performance for 2024 with record revenues and significant reimbursement progress for its flagship product, EXPAREL. However, the delayed uptake of the No Pain Act reimbursement and increased operating expenses are challenges that the company needs to navigate. The strategic acquisition of GQ Bio and expansion of commercial coverage are notable steps forward.Highlights
Record Revenues Achieved
Pacira BioSciences delivered record revenues of $701 million in 2024, reaching the high end of their guided range.
EXPAREL Reimbursement Milestone
EXPAREL received its own product-specific J code with a reimbursement rate of average selling price plus 6%, enhancing patient access and reimbursement processes.
Commercial Coverage Expansion
Commercial payers now cover roughly 40 million lives, doubling previous coverage, with TRICARE also on board.
Strategic Acquisition of GQ Bio
Pacira acquired the remaining ownership stake in GQ Bio, adding a high-capacity local delivery platform for genetic medicines.
Strong Product Portfolio Performance
All three product lines—EXPAREL, ZILRETTA, and iovera—showed sales increases, with ZILRETTA achieving $33.1 million in sales, up from $28.7 million in 2023.
Lowlights
Delayed No Pain Uptake
Although positive early signs are present, the adoption of the No Pain Act reimbursement is expected to take time, with meaningful uptake anticipated in the second half of 2025.
Increased Operating Expenses
Non-GAAP R&D expenses increased from $16.6 million to $22.0 million year-over-year, and SG&A expenses rose to $78.6 million from $57.4 million.
Company Guidance
During the Pacira BioSciences Fourth Quarter 2024 conference call, the company provided guidance for 2025, projecting total revenue between $725 million and $765 million. They anticipate volume-driven growth, with a focus on their flagship product, EXPAREL, which benefits from the NOPAIN Act's reimbursement pathway for 18 million outpatient surgical procedures. The company expects a double-digit compound annual growth rate in product revenues over the next five years and plans for a 5-percentage point expansion in gross margin from 2024 levels. Additionally, Pacira aims to advance its innovative pipeline by establishing five novel programs and forming at least five clinical or commercial partnerships by 2030. The company is also investing in targeted direct-to-consumer marketing to drive patient demand and expand product utilization.Pacira Pharmaceuticals Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Pacira Pharmaceuticals Implements New Board Leadership for Growth
Positive
Jan 30, 2025
On January 28, 2025, Pacira BioSciences announced significant changes to its Board of Directors, including the resignation of Paul J. Hastings, the Chair, and Andreas Wicki, a board member. Laura Brege was appointed as the new Chair, aligning with the company’s ongoing board refreshment strategy. These changes, alongside the reclassification of board members and committee reassignments, are part of Pacira’s 5×30 growth strategy, aimed at driving innovation and creating value in the non-opioid pain management market. This appointment marks a continued transformation of the board, ensuring the company is well-positioned to execute its strategic plan and enhance shareholder value.
Executive/Board ChangesBusiness Operations and Strategy
Pacira Pharmaceuticals Announces Leadership Changes and Plan Amendment
Positive
Jan 21, 2025
On January 21, 2025, Pacira BioSciences announced two key leadership appointments with Brendan Teehan as Chief Commercial Officer and Krys Corbett as Chief Business Officer, to advance the company’s transition into an innovative biopharmaceutical organization. These appointments are part of Pacira’s strategy to grow its commercial business and enhance its pipeline, supporting its 5×30 growth initiative. Additionally, the company amended its 2014 Inducement Plan, reserving more shares for new employees and extending the plan’s term to 2035, which could attract new talent and support its operational goals.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.